HSPA5 and COVID-19: Therefore, the present in silico outlook suggests the possibility of using orientin as an inhibitor of SARS-CoV-2 spike protein-GRP78 binding which may pave the route for drug designers to develop suitable precautionary or therapeutic modality against COVID-19.